EC
ACRS icon

EntryPoint Capital’s Aclaris Therapeutics ACRS Stock Holding History

EntryPoint Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Buy
+33,007
New +$111K 0.04% 689

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EntryPoint Capital's ACRS Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 33,007 shares worth $124K. The stake represents 0.04% of the portfolio and ranks #689 among its holdings.

136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • EntryPoint Capital held 33,007 shares of Aclaris Therapeutics worth $124K as of Q1 2026.
  • Aclaris Therapeutics was a new EntryPoint Capital position in Q1 2026.
  • Aclaris Therapeutics made up 0.04% of EntryPoint Capital's portfolio in Q1 2026, its #689 holding.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.